EA202090901A1 - Мультиспецифическое антитело - Google Patents

Мультиспецифическое антитело

Info

Publication number
EA202090901A1
EA202090901A1 EA202090901A EA202090901A EA202090901A1 EA 202090901 A1 EA202090901 A1 EA 202090901A1 EA 202090901 A EA202090901 A EA 202090901A EA 202090901 A EA202090901 A EA 202090901A EA 202090901 A1 EA202090901 A1 EA 202090901A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nucleic acid
multispecific antibody
specific antibody
binding domain
relates
Prior art date
Application number
EA202090901A
Other languages
English (en)
Inventor
Давид Урех
Теа ГУНДЕ
Себастиан Майер
Маттиас Брок
Кристиан Хесс
Александр Симонин
Штефан Вармут
Original Assignee
Нумаб Терапеутикс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нумаб Терапеутикс Аг filed Critical Нумаб Терапеутикс Аг
Priority claimed from PCT/EP2018/077509 external-priority patent/WO2019072868A1/en
Publication of EA202090901A1 publication Critical patent/EA202090901A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к мультиспецифическому антителу, включающему в себя по меньшей мере один CD137 связывающий домен и по меньшей мере один PDL1 связывающий домен, и к фармацевтическим композициям и способам их применения. Дополнительно настоящее изобретение относится к нуклеиновой кислоте, кодирующей указанное мультиспецифическое антитело, к вектору, содержащему указанную нуклеиновую кислоту, к клетке-хозяину, содержащей указанную нуклеиновую кислоту или указанный вектор, и к способу получения указанного мультиспецифического антитела.
EA202090901A 2018-06-29 2018-10-09 Мультиспецифическое антитело EA202090901A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18180814 2018-06-29
PCT/EP2018/077509 WO2019072868A1 (en) 2017-10-10 2018-10-09 MULTISPECIFIC ANTIBODIES

Publications (1)

Publication Number Publication Date
EA202090901A1 true EA202090901A1 (ru) 2020-07-10

Family

ID=62837742

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090901A EA202090901A1 (ru) 2018-06-29 2018-10-09 Мультиспецифическое антитело

Country Status (1)

Country Link
EA (1) EA202090901A1 (ru)

Similar Documents

Publication Publication Date Title
CO2020003882A2 (es) Anticuerpo multiespecifico
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
CY1123932T1 (el) Δομες πολυειδικου αντισωματος
EA201890630A1 (ru) Антитела против pd-1 и способы их применения
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
BR112016010706A2 (pt) anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira e método de produção de um anticorpo
EA201791927A1 (ru) Пиразольные соединения и способ получения и применения данных соединений
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
MX2020001198A (es) Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
CL2019001517A1 (es) Anticuerpos y métodos de su utilización.
BR112016020112A2 (pt) anticorpos multiespecíficos, método para a preparação de um anticorpo multiespecífico, ácido nucleico, vetor de expressão e composição farmacêutica
EA201891532A1 (ru) Композиции и способы лечения гемоглобинопатий
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
EA201992038A1 (ru) Анти-псф-тау-антитела и способы их применения
BR112018008051A2 (pt) vacinas de ácido nucleico para vírus de varicella zoster (vzv)
BR112017025564B8 (pt) Anticorpos anti-ctla-4 e métodos de uso dos mesmos
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
EA201890796A1 (ru) Новое антитело к мезотелину и содержащая его композиция
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
MX2017001403A (es) Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
EA201990884A1 (ru) АНТИ-C1s АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201992232A1 (ru) Композиции и способы для иммуноонкологии
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos